FDA Approves New Medication for Chronic Pain

Article

A new opioid will soon be on the market now that final approval from the United States Food & Drug Administration (FDA) has been confirmed.

A new opioid will soon be on the market now that final approval from the United States Food & Drug Administration (FDA) has been confirmed.

Wockhardt, a pharmaceutical and biotechnology company, announced it had received the go-ahead for its 5 mg/5 ml formulation of Oxycodone HCI liquid for the treatment of moderate to severe acute and chronic pain. This news comes just days after researchers revealed a new drug class to combat painful migraines and a promising non-narcotic way to treat pain.

“We are delighted to receive this ANDA approval for our Oxycodone liquid,” Habil Khorakiwala, Wockhardt founder chairman & group CEO, said in a news release.

When will Oxycodone HCI liquid officially become available? An official date has yet to be revealed, but according to the statement it will be launched “soon.” The drug will be among several other generics currently accessible for pain management.

“We have filed several ANDA’s over the last couple of years from our Morton Grove Pharmaceuticals facility in Illinois, USA, especially for liquid products,” Khorakiwala confirmed. “This is only the first of a few others we expect soon.”

The Centers for Disease Control and Prevention (CDC) stresses the importance of safety when prescribing opioids to patients with chronic pain.

Recent Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
© 2024 MJH Life Sciences

All rights reserved.